India’s third largest drugmaker by sales, Cipla Limited reported a net profit of ₹431.2 crore for the quarter ended September, a 44.4% jump over ₹299 crore in the corresponding period last year. Exports of formulations increased by 51.3% to ₹1,874 crore from ₹1,239 crore and those of active pharmaceutical ingredients (APIs) grew by 61% to ₹226 crore from ₹140 crore.